Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Piet Ost

Showing results (171-180 of 334) with videos related to

Pageof 34
Sort By:
European Urology Focus|January 16, 2019
What Is Oligometastatic Prostate Cancer?Michael Fraser, Bridget Koontz, Urban Emmenegger, et al.
International Journal of Radiation Oncology, Biology, Physics|April 28, 2010
Whole abdominopelvic radiotherapy using intensity-modulated arc therapy in the palliative treatment of chemotherapy-resistant ovarian cancer with bulky peritoneal disease: a single-institution experienceGert De Meerleer, Katrien Vandecasteele, Piet Ost, et al.
Current Oncology (Toronto, Ont.)|August 26, 2021
Extreme Hypofractionation with SBRT in Localized Prostate CancerMaria Antonia Gómez-Aparicio, Jeannette Valero, Begoña Caballero, et al.
Cancer Treatment Reviews|January 27, 2019
Oligometastatic prostate cancer: The game is afootAndrea Lancia, Thomas Zilli, Verane Achard, et al.
European Urology Open Science|June 9, 2023
Jan Vanwelkenhuyzen, Eva Van Bos, Siska Van Bruwaene, et al.
Journal of Extracellular Vesicles|April 15, 2020
Unravelling the proteomic landscape of extracellular vesicles in prostate cancer by density-based fractionation of urineBert Dhondt, Edward Geeurickx, Joeri Tulkens, et al.
Radiation Oncology (London, England)|September 24, 2017
Combined high dose radiation and pazopanib in metastatic renal cell carcinoma: a phase I dose escalation trialKatrien De Wolf, Sylvie Rottey, Karim Vermaelen, et al.
Prostate Cancer and Prostatic Diseases|December 24, 2025
Reducing adverse effects in hypofractionated radiotherapy for prostate cancer: Clinical evidence and emerging mitigation strategiesJennifer Le Guevelou, Thomas Zilli, Federica Ferrario, et al.
Frontiers in Bioscience (Landmark Edition)|January 29, 2022
Bone health and therapeutic agents in advanced prostate cancerMaria Antonia Gómez-Aparicio, Fernando López-Campos, Lira Pelari-Mici, et al.
Cancers|January 18, 2020
A Trial-Based Cost-Utility Analysis of Metastasis-Directed Therapy for Oligorecurrent Prostate CancerElise De Bleser, Ruben Willems, Karel Decaestecker, et al.
Pageof 34

Showing results (171-180 of 334) with videos related to

Sort By:
Pageof 34
European Urology Focus|January 16, 2019
What Is Oligometastatic Prostate Cancer?Michael Fraser, Bridget Koontz, Urban Emmenegger, et al.
International Journal of Radiation Oncology, Biology, Physics|April 28, 2010
Whole abdominopelvic radiotherapy using intensity-modulated arc therapy in the palliative treatment of chemotherapy-resistant ovarian cancer with bulky peritoneal disease: a single-institution experienceGert De Meerleer, Katrien Vandecasteele, Piet Ost, et al.
Current Oncology (Toronto, Ont.)|August 26, 2021
Extreme Hypofractionation with SBRT in Localized Prostate CancerMaria Antonia Gómez-Aparicio, Jeannette Valero, Begoña Caballero, et al.
Cancer Treatment Reviews|January 27, 2019
Oligometastatic prostate cancer: The game is afootAndrea Lancia, Thomas Zilli, Verane Achard, et al.
European Urology Open Science|June 9, 2023
Jan Vanwelkenhuyzen, Eva Van Bos, Siska Van Bruwaene, et al.
Journal of Extracellular Vesicles|April 15, 2020
Unravelling the proteomic landscape of extracellular vesicles in prostate cancer by density-based fractionation of urineBert Dhondt, Edward Geeurickx, Joeri Tulkens, et al.
Radiation Oncology (London, England)|September 24, 2017
Combined high dose radiation and pazopanib in metastatic renal cell carcinoma: a phase I dose escalation trialKatrien De Wolf, Sylvie Rottey, Karim Vermaelen, et al.
Prostate Cancer and Prostatic Diseases|December 24, 2025
Reducing adverse effects in hypofractionated radiotherapy for prostate cancer: Clinical evidence and emerging mitigation strategiesJennifer Le Guevelou, Thomas Zilli, Federica Ferrario, et al.
Frontiers in Bioscience (Landmark Edition)|January 29, 2022
Bone health and therapeutic agents in advanced prostate cancerMaria Antonia Gómez-Aparicio, Fernando López-Campos, Lira Pelari-Mici, et al.
Cancers|January 18, 2020
A Trial-Based Cost-Utility Analysis of Metastasis-Directed Therapy for Oligorecurrent Prostate CancerElise De Bleser, Ruben Willems, Karel Decaestecker, et al.
Pageof 34